MLYS — Mineralys Therapeutics Share News
0.000.00%
Last trade - 00:00Mineralys Therapeutics Q3 net loss narrows
Brief: Mineralys Therapeutics Q3 EPS USD -0.52
Brief: Sunoco LP Announces Results of Early Participation in Private Exchange Offers and Consent Solicitations for Outstanding Notes of Parkland Corporation and Extension of the Early Participation Exchange Consideration
Brief: Mineralys Therapeutics Presents Subgroup Analyses Of Phase 3 Launch-Htn Trial Demonstrating Efficacy And Safety Of Lorundrostat In Hypertension Participants With High Unmet Medical Need
U.S. STOCKS ON THE MOVE-Smartkem, Macy's, Dollar Tree
U.S. STOCKS ON THE MOVE-J.Jill, US airline stocks, BT Brands
U.S. STOCKS ON THE MOVE-Rev Group, BorgWarner, TechnipFMC
U.S. STOCKS ON THE MOVE-Alphabet, Zscaler, Gold miners
Mineralys Therapeutics slips after boosted $250 mln stock sale
U.S. RESEARCH ROUNDUP-BOK Financial, Sable Offshore, Zscaler
Brief: Mineralys Therapeutics Says It Announces Pricing Of Upsized $250.0 Million Underwritten Public Offering Of Common Stock
Brief: Mineralys Therapeutics Inc - Suspends Prospectus Supplement For ATM Equity Offering - SEC Filing
Brief: Mineralys Therapeutics Announces Proposed Public Offering Of Common Stock
Mineralys Therapeutics down on $175 mln stock offering plans
Mineralys Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Q2 EPS USD -0.66
Mineralys Therapeutics Inc expected to post a loss of 72 cents a share - Earnings Preview
Brief: Mineralys Therapeutics Announces Positive Topline Results From Phase 2 Trial Of Lorundrostat For The Treatment Of Hypertension
Brief: Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12